Literature DB >> 9265701

Vitreous Hemorrhage.

C W Spraul1, H E Grossniklaus.   

Abstract

The incidence of spontaneous vitreous hemorrhage is approximately 7 cases per 100,000 population. Proliferative diabetic retinopathy (32%), retinal tear (30%), proliferative retinopathy after retinal vein occlusion (11%) and posterior vitreous detachment without retinal tear (8%) are the most common causes of spontaneous vitreous hemorrhage. Vitreous hemorrhage can be caused by the pathologic mechanisms of disruption of normal retinal vessels, bleeding from diseased retinal vessels or abnormal new vessels, and extension of hemorrhage through the retina from other sources. Hemorrhage into the vitreous gel results in rapid clot formation and is followed by slow clearance of approximately 1% per day. The cellular response to vitreous hemorrhage is unusual with regard to hemorrhage in any tissue outside the vitreous cavity and has been compared to a "low-turnover" granuloma. Unique clinicopathologic features of long-standing vitreous hemorrhage include cholesterolosis bulbi (synchysis scintillans), hemoglobin spherulosis, and vitreous cylinders. Complications of nonclearing vitreous hemorrhage are hemosiderosis bulbi and glaucoma. Ghost cell glaucoma, hemolytic glaucoma, and hemosiderotic glaucoma may result from vitreous hemorrhage. The established treatment option for nonclearing vitreous hemorrhage is pars plana vitrectomy. Experimental nonsurgical treatment options involve improvement of physiologic clearance mechanisms in order to accelerate fibrinolysis, liquefaction, hemolysis and phagocytosis.

Entities:  

Mesh:

Year:  1997        PMID: 9265701     DOI: 10.1016/s0039-6257(97)84041-6

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  41 in total

1.  New applications in ultrasound technology.

Authors:  H R Atta
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Intravitreal haemoglobin spherulosis: an unusual sequela of intraocular haemorrhage.

Authors:  Elizabeth Insull; Stephen Guest; Dushyanti Samarasinghe
Journal:  Int Ophthalmol       Date:  2011-10-13       Impact factor: 2.031

3.  [Acute monocular visual loss in a child with acute lymphoblastic leukemia].

Authors:  F N Fries; M Bischoff; B Käsmann-Kellner; T Hager; B Seitz; A Viestenz
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

4.  Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.

Authors:  Qiang Yang; Kin-Sang Cho; Huihui Chen; Dekuang Yu; Wan-Heng Wang; Gang Luo; Iok-Hou Pang; Wenyi Guo; Dong Feng Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-20       Impact factor: 4.799

5.  Severe vitreous hemorrhage associated with closed-globe injury.

Authors:  Ling Yeung; Tun-Lu Chen; Ya-Hui Kuo; An-Ning Chao; Wei-Chi Wu; Kuan-Jen Chen; Yih-Shiou Hwang; Yen- Po Chen; Chi-Chun Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-26       Impact factor: 3.117

6.  Subhyaloidal and macular haemorrhage: localisation and treatment strategies.

Authors:  Stefan Mennel
Journal:  Br J Ophthalmol       Date:  2007-07       Impact factor: 4.638

7.  Terson's syndrome: surgical outcome in relation to entry site pathology.

Authors:  S Murjaneh; J E Hale; S Mishra; R H Ling; P R Simcock
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

8.  INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY DURING VITREORETINAL SURGERY FOR DENSE VITREOUS HEMORRHAGE IN THE PIONEER STUDY.

Authors:  Justis P Ehlers; Joseph F Griffith; Sunil K Srivastava
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

9.  Brilliant crystallisation in the anterior chamber and subretinal space following adjunctive intravitreal ranibizumab for diabetic vitrectomy.

Authors:  Mae-Lynn Catherine Bastion; Mushawiahti Mustapha; Ivan Ho
Journal:  BMJ Case Rep       Date:  2012-10-22

Review 10.  Vitreous haemorrhage in elderly patients: management and prevention.

Authors:  Kaykhosrov Manuchehri; Graham Kirkby
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.